Showing 5171-5180 of 5353 results for "".
- CryoShape LTD Launches One-time Scar-freezing Treatmenthttps://practicaldermatology.com/news/20120802-cryoshape_ltd_launches_one-time_scar-freezing_treatment/2459758/CryoShape LTD introduced CryoShape, a new technology to reduce or eliminate keloid and hypertrophic scars, at the Aesthetic Plastic Surgery/Anti-Aging Medicine: The Next Generation Symposium in New York City July 20-22, 2012. The product uses a
- Sandoz Completes Acquisition of Fougera Pharmaceuticalshttps://practicaldermatology.com/news/20120727-sandoz_completes_acquisition_of_fougera_pharmaceuticals/2459760/Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- gloProfessional Official Uniform Sponsor of Women's USA Field Hockey Teamhttps://practicaldermatology.com/news/20120719-gloprofessional_official_uniform_sponsor_of_womens_usa_field_hockey_team/2459769/The USA field hockey team announced a premier partnership with gloProfessional. The multi-year agreement will feature glo on the front of the Women's National Team jersey and podium suits and represents the first ever corporate advertiser
- Pycnogenol Improves Visible Signs of Aginghttps://practicaldermatology.com/news/20120718-pycnogenol_improves_visible_signs_of_aging/2459770/Pycnogenol is effective in improving visible signs of skin aging in women aged 55 to 68 years, according to a study published in a recent issue of Skin Pharmacology and Physiology. The study found that after 12 weeks of supplementing with Pycno
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Stiefel, a GSK Company, Acquires Worldwide Rights to Toctino (alitretinoin)https://practicaldermatology.com/news/20120612-stiefel_a_gsk_company_acquires_worldwide_rights_to_toctino_alitretinoin/2459784/Stiefel, a GSK company, has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. A once-daily oral retinoid, Toctino is in Phase 3 trials in the US, where it has not yet received FDA approval. Globally, it is the only prescription medicine specifically